Pepaxto

Chemical Namemelphalan flufenamide
Dosage FormInjection (intravenous; 20 mg)
Drug ClassAlkylating agents
SystemBlood
CompanyOncopeptides Inc.
Approval Year2021

Indication

  • Indicated in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
Last updated on 3/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pepaxto (melphalan flufenamide) Prescribing Information2021Oncopeptides Inc. Waltham, MA